Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

PURPOSE: Nivolumab, an anti–programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL). We report results from Cohort D of the CheckMate 205 trial, which assessed nivolumab monotherapy followed by nivolumab plus doxor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ramchandren, Radhakrishnan, Domingo-Domènech, Eva, Rueda, Antonio, Trněný, Marek, Feldman, Tatyana A., Lee, Hun Ju, Provencio, Mariano, Sillaber, Christian, Cohen, Jonathon B., Savage, Kerry J., Willenbacher, Wolfgang, Ligon, Azra H., Ouyang, Jing, Redd, Robert, Rodig, Scott J., Shipp, Margaret A., Sacchi, Mariana, Sumbul, Anne, Armand, Philippe, Ansell, Stephen M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
RAPID COMMUNICATION
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6688776/
https://ncbi.nlm.nih.gov/pubmed/31112476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00315
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados